News & Views
News,
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the…
Read more
News,
Telix announces its Annual General Meeting of shareholders to be held…
Read more
Telix announces its Annual General Meeting of shareholders to be held…
Read more
Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas,…
Read more
Telix announces its Annual General Meeting of shareholders to be held…
Read more
Telix announces its Annual General Meeting of shareholders to be held…
Read more
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1…
Read more
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Swedish MPA for the…
Read more
News,
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for…
Read more
Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced…
Read more